ATLAS_score_for_C_difficile_infection v.1
A tool to predict treatment response to Clostridium difficile infection (CDI).
To predict the treatment response (cure rate) in the cases of CDI.
To be used at the time of CDI diagnosis, for example within 48 hours of a positive C. difficile toxin assay, and when planning to administer fidaxomicin or vancomycin. ATLAS Score consists of five assessment criteria hence the abbreviation "ATLAS": - Age (<60 years: 0 point, 60-79 years: 1 point, ≥80 years: 2 points) - Treatment with systemic antibiotics for one or moredays of CDI therapy (No: 0 point, Yes: 2 points) - Leukocyte count (<16,000 cells/µL: 0 point, 16,000-25,000 cells/µL: 1 point, >25,000 cells/µL: 2 points) - Albumin (serum level) (>35 g/L: 0 point, 26-35 g/L: 1 point, ≤25 g/L: 2 points) - Serum creatinine (≤120 μmol/L: 0 point, 121-179 μmol/L: 1 point, ≥180 μmol/L: 2 points) The ATLAS score is calculated by the summation of all the points. The predicted cure rate is calculated based on the formula: Cure rate = 100 – [5.08 × (ATLAS score)]
Not to be used for continuous evaluation during the treatment.
1. Miller MA, Louie T, Mullane K, et al. Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy. BMC Infect Dis. 2013;13:148. 2. Miller MA. ATLAS - A Bedside Scoring System Predicting Mortality Due to Clostridium Difficile Infection (CDI) in Elderly Hospitalized Patients. 48th IDSA Annual Meeting. 2010;P452.
OBSERVATION.basic_demographic.v1, OBSERVATION.atlas_score_for_c_difficile_infection.v0, OBSERVATION.lab_test-full_blood_count.v1, OBSERVATION.lab_test-liver_function.v1, OBSERVATION.lab_test_creatinine.v1
